Liver damage in hemodialysis patients with hepatitis C virus viremia: A prospective 10-year study

被引:42
作者
Furusyo, N [1 ]
Hayashi, J
Kanamoto-Tanaka, Y
Ariyama, I
Etoh, Y
Shigematsu, M
Kashiwagi, S
机构
[1] Kyushu Univ Hosp, Dept Gen Med, Higashi Ku, Fukuoka 8128582, Japan
[2] Shigematsu Clin, Fukuoka, Japan
关键词
hemodialysis; hepatitis C virus; hyaluronic acid; type-IV collagen;
D O I
10.1023/A:1026696721059
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) infection is a major problem associated with hemodialysis. The extent of liver damage in hemodialysis patients with chronic HCV infection has not been thoroughly documented. The aim of this study was to evaluate liver damage of hemodialysis patients infected with HCV. A total of 233 hemodialysis patients were categorized into two groups at entry: group X, 80 positive for serum HCV RNA, and group Y, 153 negative for serum HCV RNA. All were tested for serum alanine aminotransferase (ALT) serially from 1989 to 1998, and serum hyaluronic acid (HA), serum type-IV collagen (IV-C), platelet counts, and ultrasonographic examination of the liver was done in 1998. In group X, 61.3% had continuously abnormal ALT levels for over six months followed by normal ALT levels. Of the group X patients, 11.3% had abnormal ALT levels in 1998, and in three, hepatocellular carcinoma occurred. Mean HA and IV-C levels in group X (648.8 and 188.7 ng/ml, respectively) were significantly higher than in group Y (213.1 and 165.5 ng/ml, respectively) (P < 0.05). Ultrasonographic findings significantly correlated with serum HA level and platelet counts and showed significantly more abnormalities in group X than in group Y (P < 0.05). From these findings, a combined examination with ultrasonography and serum fibrogenesis markers is useful for detection of liver damage in hemodialysis patients with HCV viremia.
引用
收藏
页码:2221 / 2228
页数:8
相关论文
共 38 条
[1]  
AKIBA T, 1994, J JPN SOC DIAL THER, V27, P77
[2]   HEPATITIS-C VIREMIA AND LIVER-DISEASE IN SYMPTOM-FREE INDIVIDUALS WITH ANTI-HCV [J].
ALBERTI, A ;
MORSICA, G ;
CHEMELLO, L ;
CAVALLETTO, D ;
NOVENTA, F ;
PONTISSO, P ;
RUOL, A .
LANCET, 1992, 340 (8821) :697-698
[3]   Liver disease in dialysis patients with antibodies to hepatitis C virus [J].
AlWakeel, J ;
Malik, GH ;
AlMohaya, S ;
Mitwalli, A ;
Baroudi, F ;
ElGamal, H ;
Kechrid, M .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (11) :2265-2268
[4]   ALTERATIONS IN SERUM ENZYMES IN CHRONIC RENAL FAILURE [J].
BAILEY, GL ;
KATZ, AI ;
HAMPERS, CL ;
MERRILL, JP .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1970, 213 (13) :2263-&
[5]   LIVER-DISEASE PATTERNS IN HEMODIALYSIS-PATIENTS WITH ANTIBODIES TO HEPATITIS-C VIRUS [J].
CARAMELO, C ;
ORTIZ, A ;
AGUILERA, B ;
PORRES, JC ;
NAVAS, S ;
MARRIOTT, E ;
ALBEROLA, ML ;
ALAMO, C ;
GALERA, A ;
GARRON, MP ;
GONZALEZPARRA, E ;
DEGABRIEL, MVF ;
OLIVA, H ;
CARRENO, V .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (06) :822-828
[6]   PREVALENCE OF HEPATITIS-C VIRUS-INFECTION IN HEMODIALYSIS-PATIENTS - A LONGITUDINAL-STUDY COMPARING THE RESULTS OF RNA AND ANTIBODY-ASSAYS [J].
CHAN, TM ;
LOK, ASF ;
CHENG, IKP ;
CHAN, RT .
HEPATOLOGY, 1993, 17 (01) :5-8
[7]   OBSERVATIONS ON DECREASED SERUM GLUTAMIC OXALACETIC TRANSAMINASE (SGOT) ACTIVITY IN AZOTEMIC PATIENTS [J].
COHEN, GA ;
GOFFINET, JA ;
DONABEDIAN, RK ;
CONN, HO .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (03) :275-280
[8]   EFFECTS OF INVIVO AND INVITRO DIALYSIS ON PLASMA TRANSAMINASE-ACTIVITY [J].
CRAWFORD, DR ;
REYNA, RS ;
WEINER, MW .
NEPHRON, 1978, 22 (4-6) :418-422
[9]   QUANTITATION OF HEPATITIS-C VIRAL-RNA IN SERA OF HEMODIALYSIS-PATIENTS - GENDER-RELATED DIFFERENCES IN VIRAL LOAD [J].
DUBOIS, DB ;
GRETCH, D ;
DELAROSA, C ;
LEE, W ;
FINE, J ;
BLAGG, CR ;
COREY, L .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1994, 24 (05) :795-801
[10]  
Furusyo N, 2000, AM J GASTROENTEROL, V95, P490, DOI 10.1111/j.1572-0241.2000.01773.x